Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-comp···【more】
Release date：2024-08-08Recommended：334
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosin···【more】
Release date：2024-08-08Recommended：350
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and bloc···【more】
Release date：2024-08-08Recommended：276
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date：2024-08-08Recommended：322
Exkivity effectively inhibits the growth and spread of tumor cells by precisely ···【more】
Release date：2024-08-08Recommended：308
Capmatinib is a MET inhibitor developed by Novartis specifically for patients wi···【more】
Release date：2024-08-08Recommended：275
Exkivityis an innovative third-representative dermal growth factor receptor (EGF···【more】
Release date：2024-08-08Recommended：258
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, prim···【more】
Release date：2024-08-08Recommended：285
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer···【more】
Release date：2024-08-08Recommended：290
Exkivity is a broad-spectrum inhibitor that broadly inhibits multiple mutant kin···【more】
Release date：2024-08-08Recommended：288
Exkivity is a new type of targeted therapy for lung cancer, which is a third rep···【more】
Release date：2024-08-08Recommended：303
Exkivity is a novel oral anti-cancer drug that acts as a small molecule tyrosine···【more】
Release date：2024-08-08Recommended：309
